Even though senescent cancer cells are less apoptosis prone due to their upregulated expression of anti-apoptosis proteins (e.g., Bcl-W, Bcl-XL and BDNF) [128,129], senescence inducers may alter treatment response of HCC cells to sorafenib, the standard-of-care for advanced HCC. Here, BDNF is linked to hepatocellular carcinoma.